{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nicotinamide+Monotherapy", "query": { "intervention": "Nicotinamide Monotherapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T03:17:20.441Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00120289", "title": "Niacin Plus Statin to Prevent Vascular Events", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Diseases", "Heart Diseases", "Cerebrovascular Accident", "Coronary Disease", "Atherosclerosis", "Myocardial Infarction" ], "interventions": [ { "name": "Extended release niacin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Axio Research. LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 3414, "start_date": "2005-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-04-06", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Pheonix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120289" }, { "nct_id": "NCT00956436", "title": "Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "BIIB022", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-08", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2013-09-16", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 6, "location_summary": "Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00956436" }, { "nct_id": "NCT01469065", "title": "A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "PF-04991532", "type": "DRUG" }, { "name": "PF-0499132", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 82, "start_date": "2011-12", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 2, "location_summary": "Chula Vista, California • Miami, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01469065" }, { "nct_id": "NCT00108953", "title": "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin/Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2005-04", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108953" }, { "nct_id": "NCT01664182", "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma", "Advanced Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Trebananib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2012-08-01", "completion_date": "2020-12-07", "has_results": true, "last_update_posted_date": "2022-06-07", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664182" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT02035527", "title": "Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Correlative Studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-04-14", "completion_date": "2017-04-20", "has_results": false, "last_update_posted_date": "2018-05-24", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02035527" }, { "nct_id": "NCT00811993", "title": "A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "RG1507", "type": "DRUG" }, { "name": "RO1507", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib [Tarceva]", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pemetrexel", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "trastuzumab [Herceptin]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2009-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 8, "location_summary": "Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811993" }, { "nct_id": "NCT01368887", "title": "Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "DPS-102", "type": "DRUG" }, { "name": "Vehicle / Placebo", "type": "OTHER" }, { "name": "Calcipotriol Monotherapy", "type": "DRUG" }, { "name": "Nicotinamide Monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "DermiPsor, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2013-04", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-09-13T03:17:20.441Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Brockton, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Brockton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01368887" } ] }